Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18

BACKGROUND: Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Doxil on surviving tumor cell immunophenotype were investigated. METHODS: Using ID...

Descripción completa

Detalles Bibliográficos
Autores principales: Alagkiozidis, Ioannis, Facciabene, Andrea, Carpenito, Carmine, Benencia, Fabian, Jonak, Zdenka, Adams, Sarah, Carroll, Richard G, Gimotty, Phyllis A, Hammond, Rachel, Danet-Desnoyers, Gwen-äel, June, Carl H, Powell, Daniel J, Coukos, George
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797002/
https://www.ncbi.nlm.nih.gov/pubmed/20003308
http://dx.doi.org/10.1186/1479-5876-7-104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797002/
https://www.ncbi.nlm.nih.gov/pubmed/20003308
http://dx.doi.org/10.1186/1479-5876-7-104

Ejemplares similares